Compare D R Horton Inc (DHI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Zimmer Biomet Holdings Inc — how do they compare? D R Horton Inc trades at $134.88 (market cap $37.99B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: D R Horton Inc is far larger — about 2.2× Zimmer Biomet Holdings Inc's market cap, and D R Horton Inc pays the higher dividend (1.33%). Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| DHI | ZBH | |
|---|---|---|
Market Cap | $37.99B | $16.95B |
Volume | 2,974,460 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $103.98 |
52-Week Low | $132.53 | $79.58 |
Typical Hold Time | 46 Days | 89 Days |
Enterprise Value | $43.09B | $24.02B |
Dividend Yield | 1.33% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $135.82, up 1.91% with a bearish technical signal despite recent earnings beats. The stock faces headwinds from rising mortgage rates impacting the housing sector, with revenue declining to $34.25B in 2025 and net income margin compressing to 9.15%. Analyst consensus remains positive with a $156.57 price target, but technical indicators show resistance at $137 with support at $133.
The outlook is mixed with strong fundamentals and attractive valuation (P/E 12.95) offset by macroeconomic pressures on housing demand. Key risks include persistent high interest rates and housing market volatility, while institutional sentiment leans bullish with 47% buy ratings. The stock offers value for long-term investors but faces near-term sector headwinds.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
